- The treatment showed improvements in swallowing difficulty scores and key disease markers.
- Eupraxia stated that it was also well tolerated across all dose levels, with no serious adverse events reported, according to Eupraxia.
- The EP-104GI treatment is backed by the company’s Diffusphere technology, which enables precise drug delivery directly into the target tissues.
Eupraxia Pharmaceuticals Inc. (EPRX) garnered retail attention on Tuesday after the biotech company reported positive data from the Phase 1b/2a portion of its RESOLVE trial evaluating treatment for eosinophilic esophagitis, a digestive system condition. Mid-stage trial data showed up to 76% remission with no serious safety concerns.
EPRX shares were up around 5% at the time of writing.
EP-104GI Shows Favorable Remission Rates
Results from the EP-104GI study showed strong clinical remission rates: 59% of patients achieved remission at 12 weeks and up to 76% at 24 weeks. Improvements were also seen in swallowing difficulty scores and key disease markers.
A new cohort using improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels, with no serious adverse events. Eupraxia’s EP-104GI is backed by its Diffusphere technology, which enables precise drug delivery directly into the target tissues.
This comes after Eupraxia reported positive data from an earlier trial of EP-104GI in January. According to the company, patients receiving the highest dose showed near-complete improvement in tissue health at 12 weeks, while patients with lower doses maintained benefits up to 36 weeks.
Last month, Eupraxia closed a public offering to raise $63.2 million. The company said it would use the gross proceeds to advance EP-104GI, including ongoing and upcoming clinical trials and preparations for a potential commercial launch. A portion of the proceeds will also support research, new clinical programs, and general corporate activities.
How Did Stocktwits Users React?
Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.
One user expects “quiet accumulation” before a “breakout attempt.”
Year-to-date, the stock has gained around 1.5%.
Also See: OKLO Stock Surges Into Retail Spotlight After Key Nuclear License Win
For updates and corrections, email newsroom[at]stocktwits[dot]com.